Wlodzimierz Lozinski

KCR SA provides clinical research services. It operates as a European contract research organization and strategic solutions provider for companies who are looking for a reliable alternative to global contract research organizations. The firm’s services include clinical trial, functional service provision, and late phase studies. It offers clinical project management, clinical monitoring, site management, feasibility studies, regulatory affairs, site start-up and contracting, biometrics and data management, quality assurance, cross-functional sourcing model, functional sourcing model, post-authorization efficacy study, post-authorization safety study, pricing and market access research, and case control study. The company was founded by Marek Kiecana in 1997 and is headquartered in Berlin, Germany.

EMC Health Care Ltd. provides health care services. The private company is based in Dublin, Ireland.

Lab-Bit Software SA provides information technology software for the medical industry. It offers software solutions to hospitals, laboratories, and clinics. The company was founded in 1996 and is headquartered Bielany Wroclawskie, Poland.

Medicover Sp zoo operates healthcare facilities. Its offer includes medical services, surgery, dietary advice, vaccinations, and treatment. The company was founded in 1997 and is headquartered in Warsaw, Poland.

Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA.

Seal Rock Therapeutics, Inc. develops molecule inhibitors apoptosis, inflammation and fibrosis. The company was founded by Kathleen Elias, Neil McDonnell and Artur Plonowski is headquartered in Seattle, WA.

Vasa Therapeutics, Inc. is a private biotechnology company based in Encinitas, CA, committed to discovering and developing transformative therapies for vascular diseases such as heart failure, peripheral artery disease, and sarcopenia. The company's cutting-edge computational chemistry and design platform integrates everything from the identification of viable biological targets to the design and identification of small molecule or peptide therapeutics. Vasa has three active preclinical programs, two small molecule programs focused on the treatment of cardiovascular disease and one peptide therapeutic program aimed at identifying a novel treatment for peripheral artery disease and sarcopenia. The company has a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits values at greater than $1b (USD). The CEO of the company is Mark Robert Herbert.